1Professor, Department of Pharmaceutical Analysis and Quality Assurance, Deccan School of Pharmacy, Darussalam, Aghapura, Hyderabad-500001, Telangana, India
2Assistant Professor, Department of Pharmaceutical Analysis and Quality Assurance, Sultan-Ul-Uloom College of Pharmacy, Mount Pleasant, Banjara Hills Road number 3, Hyderabad-500034, Telangana, India
3Student of M. Pharmacy, Department of Pharmaceutical Analysis and Quality Assurance, Deccan School of Pharmacy, Darussalam, Aghapura, Hyderabad-500001, Telangana, India
*Corresponding Author E-mail: tabraizullah96@gmail.com
Online Published on 29 May, 2026.
This study presents a detailed RP-HPLC method for quantifying Atoltivimab (ALT), Maftivimab (MFT), and Odesivimab (ODE) in the Inmazeb injection formulation. Using an Inertsil column and a 50:50 isocratic mobile phase of sodium bisulfate and acetonitrile, the flow rate was maintained at 1.0 ml/min. Detection and quantification were performed simultaneously at 236 nm. Retention times (RT) for ALT, MFT, and ODE were approximately 2.7, 3.9, and 6.2 minutes, respectively, with a linear concentration range of 8.33–25 μg/ml. The Detection limit (LOD) for ALT, MFT, and ODE were 0.050 μg/ml, 0.100 μg/ml, and 0.088 μg/ml, while the limits of quantification (LOQ) were 0.185 μg/ml, 0.333 μg/ml, and 0.293 μg/ml, respectively.
Atoltivimab, Maftivimab, Odesivimab, RP-HPLC, Inmazeb
